Introduction
On August 18th, a press conference was held at the 250th National Meeting and Exposition of the American Chemical Society (ACS) to describe the results of an analysis of lice samples collected from across the United States that would be presented at the meeting. The authors found that 104 out of the 109 lice populations tested expressed high levels of a genetic mutation resulting in resistance to pyrethroids, the most commonly used lice treatment.[1] While the findings were not entirely unexpected based on studies conducted over the past two decades, the documentation of resistance in 25 states, including Virginia, led to widespread coverage of the news in the lay press and increased concerns regarding the availability of effective treatments.[2]
Pediatr Pharm. 2015;21(9) © 2015 University of Virginia
